Biomedical subjects

P T Paradowski

Publications and source records attributed to P T Paradowski.

2 recordsLinked to original sources

PubMed1996

Pentoxifylline inhibits tumor necrosis factor alpha-induced priming of human neutrophils.

The study was designed to study the effect of pentoxifylline PTX on the chemiluminescence responses of neutrophils and on tumor necrosis factor-alpha (TNF-alpha)-induced priming of neutrophils. The results demonstrate that TNF-alpha stimulated the respiratory burst by neutrophils and primed them for enhanced response to fMLP but not to PMA. The effect of TNF-alpha on the oxygen metabolism of neutrophils was inhibited when cells were treated with PTX. This reaction was dose-dependent. Additionally, the inhibiting influence of PTX on the chemiluminescence response of neutrophils was observed.

Dose-Response Relationship, Drug↗

PubMed1995

[Pentoxifylline].

Pentoxifylline (PTX), methylxanthine derivative and phosphodiesterase inhibitor, has been in use for more than 20 years (with minimal side effects) for the potent hemorrheologic properties and was recently discovered to have influence on function of some immune cells and production of cytokines. Human and animal studies have shown that PTX therapy results in a variety of physiologic changes at the cellular level, which may be important in treating a diverse group of human afflictions. Immune modulation includes increased leukocyte deformability and chemotaxis, decreased endothelial leukocyte adhesion, decreased neutrophil degranulation and release of superoxides, decreased production of TNF-alpha and decreased NK cell activity. Potential medical uses of PTX are reviewed.

Acquired Immunodeficiency Syndrome↗